A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Inclusion Criteria:
Exclusion Criteria:
- Having received MF treatment in a clinical trial setting.
Ciudad Autonoma Buenos Aires, Ciuadad Autonoma de Buenos Aires 1199, Argentina
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1114, Argentina
São Paulo, São Paulo 05652-900, Brazil
São Paulo, 05403-000, Brazil
Montreal, Quebec H1T 2M4, Canada
Baranquilla, Atlántico 080016, Colombia
Bogota DC, Cundinamarca 111221, Colombia
Bogota, Cundinamarca 11011, Colombia
Athens, 10676, Greece
RION Patras Achaia, 26504, Greece
Cona, Ferrara 44124, Italy
Rome, Lazio 00168, Italy
Gdansk, Pomeranian Voivodeship 80-337, Poland
Lisbon, 1649-035, Portugal
Edirne, Istanbul, 22030, Turkey (Türkiye)